Intratumoral heterogeneity of cancer cells remains largely unexplored. Here we investigated the composition of ovarian cancer and its biological relevance. A whole-genome single nucleotide polymorphism array was applied to detect the clonal composition of 24 formalin-fixed, paraffin-embedded samples of human ovarian cancer. Genome-wide segmentation data consisting of the log2 ratio (log2R) and B allele frequency (BAF) were used to calculate an estimate of the clonal composition number (CC number) for each tumor. Somatic mutation profiles of cancer-related genes were also determined for the same 24 samples by next-generation sequencing. The CC number was estimated successfully for 23 of the 24 cancer samples. The mean ± SD value for the CC number was 1.7 ± 1.1 (range of 0e4). A somatic mutation in at least one gene was identified in 22 of the 24 ovarian cancer samples, with the mutations including those in the oncogenes KRAS (29.2%), PIK3CA (12.5%), BRAF (8.3%), FGFR2 (4.2%), and JAK2 (4.2%) as well as those in the tumor suppressor genes TP53 (54.2%), FBXW7 (8.3%), PTEN (4.2%), and RB1 (4.2%). Tumors with one or more oncogenic mutations had a significantly lower CC number than did those without such a mutation (1.0 ± 0.8 versus 2.3 ± 0.9, P ¼ 0.0027), suggesting that cancers with driver oncogene mutations are less heterogeneous than those with other mutations. Our results thus reveal a reciprocal relation between oncogenic mutation status and clonal composition in ovarian cancer using the established method for the estimation of the CC number.
Introduction
Ovarian cancer is the most common cause of death from gynecologic malignancy [1] . Cytoreductive surgery followed by platinum-taxane chemotherapy is the standard treatment for ovarian cancer. Although the initial response rate is >80%, most patients experience relapse within 5 years as a result of the survival of chemoresistant clones [1, 2] . A high degree of intratumoral heterogeneity for ovarian cancer also may give rise to clonal evolution, tumor progression, and resistance to chemotherapy [3, 4] . Intratumoral heterogeneity of ovarian cancer cells has remained largely unexplored, however.
Next-generation sequencing (NGS) has been applied to the molecular characterization of tumors, to the identification of new druggable targets, and to the screening of patients for clinical trials [5] . NGS technology has uncovered novel mutations in a variety of cancer types including lung cancer [5, 6] and ovarian cancer [7] . The mutation profile of cancer-related genes can now be determined by NGS from clinical formalin-fixed, paraffin-embedded (FFPE) tumor samples [8] . Mutation of the TP53 tumor suppressor gene has been detected in >50% of ovarian cancers, predominantly in those at an advanced stage and with high-grade serous histology [9] . Mutations in BRAF, KRAS, PTEN, or CTNNB1 have also been identified in ovarian tumors with endometrioid, mucinous, or low-grade histologies [10] .
Copy number variations reflect genomic structural changes that give rise to gene amplification, deletion, or copy number gain and which result from selection pressures that favor cancer development. Chromosomal microarray and other array-based approaches have been widely adopted for detection of whole-genome copy number variation [11, 12] , but they can be difficult to perform with FFPE samples. The OncoScan ® FFPE Assay Kit (a research use only product from Thermo Fisher Scientific) relies on molecular inversion probe (MIP) technology to detect genome-wide copy number alterations, loss of heterozygosity, and somatic mutations [13] . This assay provides the B allele frequency (BAF), log2 ratio (log2R), and copy number for each of~220,000 analyzed polymorphic genomic locations. Copy number is derived from log2R and BAF. We hypothesized that clonal composition of a tumor can be analyzed on the basis of BAF and log2R, determined from whole-genome copy number profiles obtained with the OncoScan ® FFPE Assay Kit. A similar approach had been described in Ref. [14] , where clonal composition was derived from both somatic mutations as well as log2Rand BAF for loci with aberrant copy number. Others have previously described approaches mainly based on the variant allele frequency (VAF) of somatic mutations, [15e17]. We have now examined the feasibility of this approach with retrospectively collected FFPE samples of ovarian cancer FFPE samples of ovarian cancer. In addition, we examined the relation between mutation profile and clonal composition. Our results suggest that the presence of somatic mutations in ovarian cancer may be associated with a lower clonal composition (CC number).
Materials and methods

Ovarian cancer samples
Twenty-four previously untreated ovarian cancer samples were enrolled in this retrospective study. All cases were assigned a stage based on the 1988 International Federation of Gynecology and Obstetrics (FIGO) system.
Isolation of genomic DNA
Collected FFPE samples were subjected to a histological review, and only those containing sufficient tumor cells as determined by hematoxylin and eosin staining were subjected to DNA extraction. Genomic DNA was extracted from FFPE tumor samples with the use of a QIAamp DNA FFPE Kit (Qiagen, Valencia, CA). The quality and quantity of the DNA were determined with the use of a Thermo Scientific™ NanoDrop™ 2000/2000c Spectrophotometers (Thermo Fisher Scientific, Waltham, MA) and Invitrogen™ Quant-iT™ PicoGreen™ dsDNA Assay Kit (Thermo Fisher Scientific).
Sequencing analysis
Tumor DNA samples were analyzed with NGS panels for mutation detection. For library preparation, the DNA was subjected to multiplex amplification by the polymerase chain reaction (PCR) with the use of an Ion AmpliSeq™ Library Kit 2.0 and Ion AmpliSeq™ Cancer Hotspot Panel v2 (Thermo Fisher Scientific). The PCR products were ligated to Ion Xpress™ Barcode Adapters 1e16 Kit (Thermo Fisher Scientific) and purified with the use of Agencourt AMPure XP beads (Beckman Coulter, Brea, CA). The purified libraries were pooled and then sequenced with an Ion Proton™ System, Ion PI™ Hi-Q™ Sequencing 200 Kit and Ion PI™ Chip Kit v3 (all from Thermo Fisher Scientific). DNA sequencing data were accessed through the Torrent Suite™ Software v.4.4 program (Thermo Fisher Scientific). Reads were aligned with the hg19 human reference genome, and potential mutations were called with the use of Variant Call Format ver. 5.0. Raw variant calls were filtered with a quality score of <100 and were manually checked with the integrative genomics viewer (IGV; Broad Institute, Cambridge, MA). Germline mutations were excluded with the use of the Human Genetic Variation Database (http://www. genome.med.kyoto-u.ac.jp/SnpDB).
Array-based readout
DNA isolated from FFPE samples was analyzed with an OncoScan ® FFPE Assay Kit (Thermo Fisher Scientific). Oncoscan FFPE Assay Kit contains~220,000 molecular inversion probes (MIPs) that measure both the A (A/T) and B (G/C) allele at these (A/ B) polymorphic loci.
In the Oncoscan FFPE Assay Kit, DNA (80 ng) is subjected to annealing with these MIPs for 16e18 h followed by enzyme digestion and two separate gap-fill reactions. The circular MIPs are then separately linearized for each gap fill with a cleavage enzyme and amplified by PCR. The PCR products are subjected to enzymatic cleavage and fragmentation followed by hybridization for 16e18 h with two OncoScan ® arrays, (one for each gap fill). The arrays are then stained and washed with the use of a GeneChip Fluidics Station 450 and loaded into a GeneChip Scanner 3000 7G (Thermo Fisher Scientific). Array fluorescence intensity (CEL) files were generated with Affymetrix GeneChip Command Console (AGCC) software version 4.0, and the CEL files were converted to OSCHP files with OncoScan Console software 1.3.
Clonal composition analysis
The OncoScan ® FFPE Assay Kit provides genome-wide segmentation data, with each segment having a log2R and BAF. Cancer samples are rarely pure and almost always have normal tissue contamination. In addition, cancer samples frequently have multiple clones. We assume, as was done in Ref. [14] , that a given abnormal copy number segment is the result of a single underlying event attributable to a single clone. Indeed, rarely do different clones affect the same copy number segment. Therefore, as assumed in Ref. [14] , a given copy number segment can be associated with a %AC e the percentage of aberrant tumor cells. Hence we assume that copy number segments associated with the same %AC belong to the same clone. OncoScan FFPE Assay Kit reports a single %AC if the vast majority of copy number changes are consistent with the same %AC, otherwise a value of NA is reported. Onco Clone Composition clusters segments with similar log2R and BAF and assigns a %AC to each such cluster. A second clustering is done to combine clusters assigned to the same %AC.
We now proceed to show how the %AC is derived from the log2R and BAF value of a segment. The log2R value is a function of the percentage of aberrant tumor cells (%AC) that contribute to the copy number alteration and of the copy number (C) in the cancer genome. In particular, for %AC ¼ b, log2R has the following relationship to b ¼ %AC.
Where g is a technology factor. For example, for b ¼ 0.2 (%AC ¼ 20%), 20% of cells have C copy number, while 80% cells have 2 copies. BAF is defined by the equation.
Where A and B correspond to the number of A alleles and B alleles, respectively. The number of A alleles and B alleles depends again on the %AC, the copy number C in the cancer genome and the allelic imbalance in the cancer genome. The number of minor alleles at a heterozygous site (NOMA) [18] , helps in defining the BAF of a segment. For normal segments (C ¼ 2) NOMA is 1, given that both alleles are present at each heterozygous site. However, for a segment with 100% loss of heterozygosity and normal copy number (C ¼ 2), NOMA is 0, given that only one of the alleles is present, and the BAF of such a segment is zero. In a segment with %AC ¼ b, copy number C in the tumor portion, and NOMA ¼ k, the number of A alleles at a heterozygous site with less A alleles is bk þ (1Àb), while the copy number of the segment is bC þ2 (1Àb). The BAF of such a segment can hence be written as:
The key observation is that by combining Equations (1) and (3) for any given segment we get
As a result when plotting log2R versus log 2 (BAF cs ) all copy number segments from a given clone with %AC ¼ b and with same k (NOMA) form a straight line with intercept 1Àlog (bk þ (1Àb)), and constant slope 1/g. Segments with k ¼ 0 and various copy numbers are particularly easy to analyze as the corresponding intercept is 1Àlog (1Àb) and the relationship to b is obvious. In default mode Onco Clone composition only uses NOMA ¼ 0 segments to estimate the CC number, which in practice gave the best results. Fortunately, such segments are very common in cancer research samples. They correspond to segments with loss of heterozygosity in the cancer, and residual heterozygosity from the normal tissue. Segments with k ¼ 1, do not provide information on the %AC (b), because b cancels out in the equation log (bk þ (1Àb)). Such segments are hence not informative for their association with a given clone. Analysis of the clonal composition number corresponds to the identification of the number of different b ¼ %AC terms detected among the aberrant segments. This analysis determines a clone to be positive if the percentage of markers in the aberrant segments assigned to a given b is more than 1% of all~220,000 markers.
The 1% cut-off was validated by mixing studies of tumors with various amounts of matched normals and assures that noise in the data does not affect the results. The Onco Clone Composition program provides a graphical representation of the aberrated segments and their association to %AC, as well as analytical estimation of the clonal composition by using a clustering approach that clusters all segments with same logR and BAF and then combines clusters corresponding to the same % AC. Each solid circle, cross, diamond, and square in Fig. 2 corresponds to the theoretical position of a segment with a given copy number and given %AC (color coded by %AC from 20% to 90%, as per the legend of the figure) . Each open red circle corresponds to one segment in the cancer sample. Red circles turn yellow upon selection of one or more clone, as seen in Fig. 2 , where all clusters representing a clone were selected. The remaining red circles were either not associated with a % AC, or correspond to NOMA>0 segments. Visually, the clusters formed by the segments in the sample are easy to see, and the lines formed by the clusters of yellow dots, corresponding to segments with the same %AC and different copy number, are striking. The summary of CC number is provided by the clustering algorithm. For example, in Fig. 2C all yellow dots overlap the "theoretical location" of segments with 55% AC (shown in gray), while in Fig. 2B we see 2 straight lines, corresponding to roughly 60% AC and 35% AC.
In some cases, the number of clones reported by the tool is zero. Since the number of clones is derived from the aberrated copy number segments, this can happen when no copy number changes are present (as in Example 10) or when the segments with copy number changes are either too few (less than 1% of markers) or are non-informative as explained earlier (as in Examples 13 and 17).
High ploidy samples can sometimes be confused with multi clone samples. We rely here on the OncoScan algorithms to "center" the samples correctly and recognize high ploidy. Triploid samples are almost always correctly centered and their log2R is adjusted accordingly. Samples with ploidy four are extremely challenging and are not always detected.
Statistical analysis
Categorical variables were compared with the chi-square test. Continuous variables were compared between groups with the Mann-Whitney U test. All statistical analysis was performed with Prism software (GraphPad Software, San Diego, CA). A P value of <0.05 was considered statistically significant.
Results
Determination of clonal composition of ovarian tumors from the whole-genome copy number profile
Tumor samples are typically heterogeneous, containing an admixture of noncancerous cells and one or more subpopulations of cancerous cells. We analyzed 24 FFPE samples of ovarian tumors with the use of a whole-genome single nucleotide polymorphism (SNP) array. The genome-wide copy number screen identified a heterogeneous pattern in the BAF profile. In BAF plots, a value of 0.5 indicates a heterozygous genotype (AB), whereas 0 and 1 indicate homozygous genotypes (AA and BB, respectively). BAF values are less predictive in genomic regions with copy number gain because of an interplay between the extent of copy number gain versus normal contamination, where different combinations of normal contamination and tumor copy number state give identical BAF value. On the other hand, BAF values for genomic regions with copy number loss do not have that limitation and the normal contamination can be derived from the BAF value. In regions with no copy number gain, the possible states are limited to those reflecting the normal state, loss of heterozygosity (LOH), or homozygous deletion if the aberrated region is affected by a single clone. We therefore focused on the BAF distribution at genomic regions with no copy number gain.
One endometrioid ovarian cancer sample (Example no. 19) manifested a different pattern in the BAF profile at chromosomal regions 8p12-22 and 12q (Fig. 1A) . The 8p12-22 region showed a median log2R of À0.47 and BAF values of 0, 0.40, 0.60, and 1, whereas the 12q region showed a median log2R of À0.36 and BAF values of 0, 0.23, 0.77, and 1. Another sample with a serous histology (Example no. 1) also exhibited a different pattern in the BAF profile at 6q24-27 and 7q21-31 (Fig. 1B) . The 6q24-27 region showed a median log2R of À0.40 and BAF values of 0, 0.30, 0.70, and 1, whereas 7q21-31 showed a median log2R of À0.27 and BAF values of 0, 0.40, 0.60, and 1. Variation in BAF profile for regions with copy number loss or neutral regions is thought to reflect admixture of cells with different allelic imbalance. Segment analysis of log2R and BAF can thus provide an estimate of the number of cell clones in a tumor.
We established a method for the estimation of the clonal composition number (CC number) in tumor tissue from its wholegenome copy number profile. The CC number is not equivalent to the number of clones in the tumor tissue, but represents an estimate of the number of clones that show copy number changes.
Automated analysis with the Onco Clone Composition estimation program yielded an estimate for the CC number in 23 of the 24 ovarian cancer samples. The mean ± SD value for the CC number was 1.7 ± 1.1 (range, 0e4) . It was not possible to estimate the CC number for the remaining specimen (Example no. 15) because the copy number data did not plot onto the fitting curve in the CC estimation program. Representative plots for the CC profile are shown in Fig. 2 . Three clusters were detected in Example number 11, with the percentage of markers in the clusters being 32.1%, 4.9%, and 2.8% ( Fig. 2A) ; two clusters were detected in Example number 1, with the percentages of markers being 37.4% and 1.7% (Fig. 2B) , and one cluster was detected in Example number 8, with the percentage of markers in the cluster being 36.4% (Fig. 2C) . In total, we identified a CC number of 4 in one case (4.3%), 3 in four cases (17.4%), 2 in eight cases (34.8%), 1 in seven cases (30.4%), and 0 in three cases (13.0%) ( Fig. 2, Supplementary Figure S1 ). The CC estimation program was thus shown to identify clusters of aberrations from different clones and thus provide a measure of intratumor heterogeneity.
Mutation profiling of ovarian cancer
We also determined somatic mutation profiles for 50 cancerrelated genes by NGS for the 24 ovarian cancer samples (Fig. 3) . Amplicon sequencing was performed successfully for all samples. Somatic missense mutations were identified in 22 (91.7%) of the 24 samples ( Supplementary Table S1 ) and included 14 potentially relevant oncogene mutations that were categorized by Cancer Gene Census in COSMIC database (http://cancer.sanger.ac.uk/census) and UniProt Knowledgebase (http://www.uniprot.org/uniprot/), KRAS (7/24, 29.2%), PIK3CA (3/24, 12.5%), BRAF (2/24, 8.3%), FGFR2 (1/24, 4.2%), and JAK2 (1/24, 4.2%). Mutations of the tumor suppressor genes TP53, FBXW7, PTEN, and RB1 were also detected in 13 (54.2%), and 1 (C) . The x-axis depicts the log2R of BAF, and the y-axis the log2R for copy number. The size of each symbol reflects copy number, the percentage of aberrant tumor cells (%AC) is differentiated by color, and the number of minor alleles at a heterozygous site (NOMA) is indicated by the different symbols (circle, cross, diamond, and square for values of 0, 1, 2, and 3, respectively). The open circles represent chromosome location of the segments of the sample analyzed, red ¼ chromosomes 1e22, whereas the blue ¼ chromosomes X and Y. These symbols form a fixed backbone and represent the fixed theoretical points corresponding to the various %AC as indicated by the legend on the left, blue for 20%, orange for 25%, etc. The CC number was estimated within regions where NOMA ¼ 0. Points with the same %AC correspond to the same clone. The lower panels show the graphical representation of log2R and BAF for each aberrant segment indicated by the numbered yellow circles in each upper panel. Each open circle corresponds to one segment in the cancer sample. All selected clones with their associated %AC were selected and the corresponding segments turn yellow. The remaining red circles were either not associated with a %AC, or correspond to NOMA>0 segments. 2 (8.3%), 1 (4.2%), and 1 (4.2%) samples, respectively. Potentially relevant oncogene mutations were detected more frequently in nonserous-type (including endometrioid, clear cell, and mucinous) tumors than in serous tumors (81.8% versus 23.1%; P ¼ 0.0041, chisquare test), consistent with previous findings [19, 20] .
Relation of clonal composition to oncogenic mutations and pathological characteristics
We next examined the possible relation between CC number and mutation status or pathological characteristics for ovarian tumors. Tumor histology, stage, CC number, and mutation status are shown in Fig. 3 . The CC number was classified into two groups of high (!2) or low (0 or 1) for comparison with pathological characteristics and mutation status ( Table 1 ). There was no significant difference in age, disease stage, or tumor histology between these two groups. A significant difference in oncogenic mutation status was detected (P ¼ 0.0067), however. We then further compared the CC number between histological types and oncogenic mutation states. Whereas the CC number did not differ significantly between serous and nonserous histologies (Fig. 4A) , it was significantly lower in tumors with one or more oncogenic mutations than in those without such mutations (1.0 ± 0.8 versus 2.3 ± 0.9, P ¼ 0.0027), suggesting that tumors with oncogenic mutations have a lower CC number compared with those with other mutations including tumor suppressor genes (Fig. 4B ).
Discussion
Tumor clonality is an important determinant of both tumor biology and potential treatment. Genome-wide approaches such as genome alteration print (GAP) and allele-specific copy number analysis of tumors (ASCAT) provide an informative graphic presentation of normal cell content and estimate of tumor fraction [21, 22] . However, a quantitative analytic program for calculation of tumor clonality has not been available. We hypothesized that BAF distribution for each genomic location in SNP analysis might be informative with regard to distinguishing intratumor clonality. We developed a bioinformatics approach to such analysis, which we have now successfully applied to determine the clonal composition of clinical FFPE samples of ovarian cancer tissue. Future validation of this approach might be achieved by examining the concordance between the CC number determined by the program and intratumoral histopathologic heterogeneity, although the heterogeneous nature of ovarian cancer may hinder such a comparison.
We also hypothesized that tumors with a high clonality might have a high general mutation burden, whereas tumors with driver mutations might comprise fewer clones. Examination of the relation between CC number and mutation profile obtained by amplicon-based NGS for ovarian cancer samples revealed that tumors with one or more oncogenic mutations had a significantly lower CC number, suggesting that ovarian tumors with oncogene mutations have fewer clones than those with other mutations.
Our NGS analysis detected several somatic mutations including those in both oncogenes and tumor suppressor genes in ovarian cancer, with the frequencies of these mutations being similar to those previously reported [10, 20] . Some oncogene mutations have been found to serve as druggable targets for molecularly targeted agents in several cancers including melanoma and nonesmall cell lung cancer. We classified ovarian cancer samples into two groups based on the absence or presence of such potentially relevant oncogene mutations. Papillary serous adenocarcinoma accounted for a larger number of ovarian tumors without the oncogene mutations than did other types of epithelial ovarian cancer, consistent with previous observations [20] , although this difference was not significant. TP53 mutations were also frequently detected in the serous type of ovarian cancer in our sample cohort, consistent with previous findings [19, 20] .
Despite treatment with cytoreductive surgery and platinumand taxane-based chemotherapy, >70% of patients with advanced ovarian cancer, who achieve remission, ultimately experience relapse. The development of new treatment strategies for these is thus urgently needed [20] .
Recent advances in immunotherapy such as that with antibodies to CTLA-4 or to PD-1 have resulted in marked clinical responses in some patients. We previously demonstrated clinical efficacy of the antiePD-1 antibody nivolumab in patients with platinum-resistant ovarian cancer [23] . However, biomarkers that could allow selection of patients likely to receive clinical benefit from such immune checkpoint blockade therapy remain to be identified. Exome sequencing of melanoma showed that tumors harboring a higher number of mutations tended to respond well to immunotherapy. The high mutation burden might facilitate recognition of cancerous cells by the immune system and thereby render such patients strong candidates for checkpoint blockade therapy [24] . No evidence is available for association between CC number and mutation burden in this paper. Therefore, we will clarify this association in the following study in addition to a validation study using another sample cohort.
In conclusion, we have found a reciprocal relationship between the oncogenic mutation status and clonal composition. The biological relevance provides a meaningful indicator of intratumoral heterogeneity for ovarian cancer. Oncogenic mutation Negative Positive Fig. 4 . Relation between CC number and tumor histology or oncogenic mutation status for ovarian cancers. (A) Lack of association (P ¼ 0.337) between CC number and tumor histology (serous versus nonserous). (B) Significant association (*P ¼ 0.0027) between CC number and the absence or presence of a potentially relevant missense mutation in the oncogenes KRAS, BRAF, PIK3CA, FGFR2, or JAK2. Mean ± SD values are also indicated. The significance of differences in CC number was analyzed with the chi-square test.
